Maravai LifeSciences Holdings Inc (MRVI) concluded trading on Thursday at a closing price of $8.61, with 2.54 million shares of worth about $21.85 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 8.99% during that period and on September 12, 2024 the price saw a loss of about -2.27%. Currently the company’s common shares owned by public are about 132.23M shares, out of which, 117.52M shares are available for trading.
Stock saw a price change of -0.35% in past 5 days and over the past one month there was a price change of 2.01%. Year-to-date (YTD), MRVI shares are showing a performance of 31.45% which decreased to -16.41% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.52 but also hit the highest price of $11.56 during that period. The average intraday trading volume for Maravai LifeSciences Holdings Inc shares is 2.38 million. The stock is currently trading -2.79% below its 20-day simple moving average (SMA20), while that difference is down -0.93% for SMA50 and it goes to 11.55% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) currently have 132.23M outstanding shares and institutions hold larger chunk of about 90.00% of that.
The stock has a current market capitalization of $1.22B and its 3Y-monthly beta is at 0.01. It has posted earnings per share of -$1.00 in the same period. It has Quick Ratio of 9.28 while making debt-to-equity ratio of 1.29. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MRVI, volatility over the week remained 6.80% while standing at 6.92% over the month.
Stock’s fiscal year EPS is expected to drop by -208.86% while it is estimated to increase by 166.59% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on August 28, 2024 offering an Overweight rating for the stock and assigned a target price of $10 to it. Coverage by Morgan Stanley stated Maravai LifeSciences Holdings Inc (MRVI) stock as an Equal-weight in their note to investors on August 13, 2024, suggesting a price target of $10 for the stock. On April 10, 2024, Craig Hallum Initiated their recommendations, while on December 12, 2023, BofA Securities Upgrade their ratings for the stock with a price target of $8. Stock get a Sector weight rating from KeyBanc Capital Markets on August 08, 2023.
